| Literature DB >> 26147347 |
Yukihisa S Watanabe1, Yoshika Yasuda1, Yuko Kojima2, Shino Okada3, Tomoko Motoyama3, Ryo Takahashi4, Mitsuru Oka1.
Abstract
The single-crystal structure of anagliptin, N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide, was determined. Two independent molecules were held together by intermolecular hydrogen bonds, and the absolute configuration of the 2-cyanopyrrolidine ring delivered from l-prolinamide was confirmed to be S. The interactions of anagliptin with DPP-4 were clarified by the co-crystal structure solved at 2.85 Å resolution. Based on the structure determined by X-ray crystallography, the potency and selectivity of anagliptin were discussed, and an SAR study using anagliptin derivatives was performed.Entities:
Keywords: Co-crystal structure; DPP-4 inhibitor; X-ray crystallography; transition-state interaction; type 2 diabetes
Mesh:
Substances:
Year: 2015 PMID: 26147347 DOI: 10.3109/14756366.2014.1002402
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051